
Browsing restrictions can be lifted for a fee.
-13.09%
Moolec science s.a.
0.05%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and pipeline leverage the agronomic efficiency of used target crops, such as soybeans and peas. It operates in the United States, Europe, and South America. The company was founded in 2008 and is based in Luxembourg.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Moolec science s.a. (MLECW) covers the period of 2024Q2 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MLECW's short-term business performance and financial health. For the latest updates on MLECW's earnings releases, visit this page regularly.
According to the latest financial report, Moolec science s.a. (MLECW) reported an Operating Profit of -2.06M with an Operating Margin of -77.92% this period, representing a decline of 3.86% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Moolec science s.a. (MLECW) announced revenue of 2.64M, with a Year-Over-Year growth rate of 948.32%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
As of the end of the reporting period, Moolec science s.a. (MLECW) had total debt of 22.09M, with a debt ratio of 0.7. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
At the end of the period, Moolec science s.a. (MLECW) held Total Cash and Cash Equivalents of 1.93M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Moolec science s.a. (MLECW) did not achieve the “three margins increasing” benchmark, with a gross margin of -25.52%%, operating margin of -77.92%%, and net margin of -91.84%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess MLECW's profit trajectory and future growth potential.
According to the past four quarterly reports, Moolec science s.a. (MLECW)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Moolec science s.a. (MLECW)'s Free Cash Flow (FCF) for the period is -1.19M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 70.64% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Moolec science s.a. (MLECW) has a Price-To-Earnings (PE) ratio of -3.21 and a Price/Earnings-To-Growth (PEG) ratio of -0.16. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.